Your browser doesn't support javascript.
loading
Successful autologous hematopoietic stem cell transplantation in a refractory anti-Caspr1 antibody nodopathy.
Afanasiev, Vadim; Tsouni, Pinelopi; Kuntzer, Thierry; Cairoli, Anne; Delmont, Emilien; Vallat, Jean-Michel; Devaux, Jérôme; Théaudin, Marie.
Afiliación
  • Afanasiev V; Department of Neurology, Neurocentre, Hôpital du Valais, Sion, Switzerland.
  • Tsouni P; Department of Neurology, Neurocentre, Hôpital du Valais, Sion, Switzerland.
  • Kuntzer T; Department of Clinical Neuroscience, University Hospital of Lausanne (CHUV), and University of Lausanne, Lausanne, Switzerland.
  • Cairoli A; Department of Hematology, University Hospital of Lausanne (CHUV), and University of Lausanne, Lausanne, Switzerland.
  • Delmont E; Referral Centre for Neuromuscular Diseases and ALS, La Timone Hospital, Marseille, France.
  • Vallat JM; Department and Laboratory of Neurology, National Reference Center for 'Rare Peripheral Neuropathies', University Hospital of Limoges (CHU Limoges), Limoges, France.
  • Devaux J; Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, Montpellier, France.
  • Théaudin M; Department of Clinical Neuroscience, University Hospital of Lausanne (CHUV), and University of Lausanne, Lausanne, Switzerland.
J Peripher Nerv Syst ; 29(1): 116-119, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38123899
ABSTRACT

AIM:

Autoimmune nodopathies have specific clinicopathologic features, antibodies directed against nodal proteins (neurofascin 186) or paranodal proteins (neurofascin 155, contactin 1, contactin-associated protein 1 (Caspr1)), and usually have a poor response to first-line therapies for chronic inflammatory demyelinating polyradiculoneuropathy. Anti-Caspr1 nodopathy treated with autologous hematopoietic stem cell transplantation (AHSCT) has not been previously reported.

METHODS:

We report the first case of an anti-Caspr1 antibody-positive nodopathy refractory to high-intensity immunosuppressive treatment, including rituximab, that responded dramatically to AHSCT.

RESULTS:

A 53-year-old woman presented with a rapidly progressive generalized ataxic, painful motor, and inflammatory neuropathy supported by neurophysiologic and MRI studies. Initial tests for antibodies to nodal/paranodal proteins were negative. She was treated with multiple courses of intravenous immunoglobulin and methylprednisolone, plasma exchange, rituximab, and cyclophosphamide without significant clinical benefit. Repeated testing for antibodies to nodal/paranodal proteins yielded a positive result for anti-Caspr1/IgG4 isotype antibodies. Given the poor response to multiple high intensity treatments and the relatively young age of the patient, we decided to perform AHSCT at 30 months post-onset. Immediately after AHSCT, she stopped all immunomodulatory or immunosuppressive therapy. The Overall Neuropathy Limitation Score improved from 8/12 to 4/12 at 6 months post-AHSCT. At 3 months post-AHSCT, IgG4 against Caspr1 was negative and no reactivity against paranodes could be detected.

CONCLUSION:

We report a particularly severe anti-Caspr1 antibody autoimmune nodopathy that responded dramatically to AHSCT. Although the rarity of the disease limits the possibility of larger studies, AHSCT may be a valuable therapy in treatment-refractory cases.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante Límite: Child, preschool / Female / Humans / Middle aged Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante Límite: Child, preschool / Female / Humans / Middle aged Idioma: En Año: 2024 Tipo del documento: Article